# US 2023/0026163 A1 · Anticancer compound and medical use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0026163 A1
- Document ID: US20230026163A1
- Status: Published application
- Kind: A1
- Application number: 17/778,828
- Filed: 2020-09-10
- Published: 2023-01-26
- Earliest claimed: 2019-12-20
- Assignees: Ascentawits Pharmaceuticals, Ltd.
- Applicants: Ascentawits Pharmaceuticals, Ltd.
- Inventors: Anrong LI; Jianxin DUAN; Fanying MENG; Xiaohong CAI
- Web page: https://patentgrep.com/patent/US20230026163A1

## CPC

- C07F 9/564: Three-membered rings
- A61K 31/664: Amides of phosphorus acids
- A61K 31/675: having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07F 9/60: Quinoline or hydrogenated quinoline ring systems
- C07F 9/650994: {condensed with carbocyclic rings or carbocyclic ring systems}
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of formula (I), or pharmaceutically acceptable salts, solvates, isotopic variants, or isomers thereof, and anticancer medical use are provided.

## Claims

### Claim 1

A compound of formula (I), or a pharmaceutically acceptable salt, a solvate, an isotopic variant, or an isomer thereof:
wherein
Cx is a 5- to 10-membered aryl ring or heteroaryl ring, a heteroaliphatic ring or a cycloalkane, and the Cx shares two carbons with the nitrobenzene ring to form a fused ring structure;
R1 is attached to any skeleton atom of the Cx ring, and the R1 is selected from a hydrogen, a halogen atom, a cyano or isocyano group, an hydroxyl group, an thiol group, an amine, an OTs, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, a C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a Z-substituted aryl group, a 4- to 15-membered heterocycle or a Z-substituted heterocycle, a 5- to 15-membered heteroaryl group or a Z-substituted heteroaryl group, an alkoxyl group with 1-6 carbon atoms or a Z-substituted alkoxyl group with 1-6 carbon atoms, —CONR6R7, —SO2NR6R7, —SO2R6, —OCOO—R6, —COOR6, —NR6COR7, —OCOR6, —NR6SO2R7, or —NR6SO2NR6R7;
R2 and; R3 are each respectively a hydrogen, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, a C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a Z-substituted aryl group, a 4- to 15-membered heterocycle or a Z-substituted heterocycle, a 5- to 15-membered heteroaryl group or a Z-substituted heteroaryl group, or a 3- to 6-membered ring formed by R2, R3, and the bonded carbon atom at the benzylic position;
group replaces a hydrogen atom at any position on a carbon atom of the fused ring, and a number of substitutions is 1;
the Z-substituted group is a halogen atom, a cyano or isocyano group, a hydroxyl group, a thiol group, an amine group, a C1-C3 alkyl group or a substituted alkyl group, a C1-C3 alkoxyl group or a substituted alkoxyl group, a C2-C3 alkenyl group or a substituted alkenyl group, C2-C3 alkynyl group or a substituted alkynyl group, or a C3-C8 cycloalkyl group or a substituted cycloalkyl group;
R6 and R7 are each respectively a hydrogen, a C1-C6 alkyl group or a Z-substituted alkyl group, a C2-C6 alkenyl group or a C2-C6 Z-substituted alkenyl group, a C2-C6 alkynyl group or a Z-substituted alkynyl group, C3-C8 cycloalkyl group or a Z-substituted cycloalkyl group, a C6-C10 aryl group or a C6-C10 Z-substituted aryl group, a 4- to 15-membered heterocylic group or a Z-substituted 4- to 15-membered heterocyclic group, 5- to 15-membered heteroaryl group or a Z-substituted 5- to 15-membered heteroaryl group, or a 5- to 7-membered heterocyclic group or a Z-substituted 5- to 7-membered heterocyclic group formed by R6, R7, and an atom bonded thereto.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the Cx is
a 5-, 6-, or 8-membered aryl ring; or
a 5-, 6-, 7-, or 8-membered heteroacryl ring or aliphatic heterocycle containing N, O, or S atoms; or
a 5-, 6-, 7-, or 8-membered aliphatic ring.

### Claim 3 (depends on 1)

The compound of claim 1, which is a compound of formula (II):
wherein
R1 substitute a hydrogen atom at any position on carbon atom of a fused ring, and a member of the substituent R1 is 1, 2, 3, 4, 5, or 6;
X is C or N.

### Claim 4 (depends on 3)

The compound of claim 3, wherein
only one or two of the four X atoms are N atoms.

### Claim 5 (depends on 3)

The compound of claim 3, wherein,
R1 is the hydrogen, the halogen atom, the C1-C6 alkyl group or the Z-substituted alkyl group, the C3-C8 cycloalkyl group or the Z-substituted cycloalkyl group, the C6-C10 aryl group or the Z-substituted aryl group, the 4- to 15-membered heterocycle or the Z-substituted heterocycle, or the 5- to 15-membered heteroaryl group or the Z-substituted heteroaryl group; or
R2 and R3 are each respectively the hydrogen, the C1-C6 alkyl group or the Z-substituted alkyl group, the C3-C8 cycloalkyl group or the Z-substituted cycloalkyl group, the C6-C10 aryl group or the Z-substituted aryl group, the 4- to 15-membered heterocycle or the Z-substituted heterocycle, or the 5- to 15-membered heteroaryl group or the Z-substituted heteroaryl group.

### Claim 6 (depends on 5)

The compound of claim 5, wherein,
R1 is the hydrogen, the C1-C6 alkyl group or a halogen substituted C1-C6 alkyl group, the C3-C8 cycloalkyl group or a halogen substituted C3-C8 cycloalkyl group, or the C6-C10 aryl group or a halogen substituted C6-C10 aryl group; or
R2 and R3 are each respectively the hydrogen, the C1-C6 alkyl group or a halogen substituted C1-C6 alkyl group, the C3-C8 cycloalkyl group or a halogen substituted C3-C8 cycloalkyl group, or the C6-C10 aryl group or a halogen substituted C6-C10 aryl group.

### Claim 7 (depends on 6)

The compound of claim 6, wherein
R1 is H, —CH3, or —CF3;
R2 and R3 are respectively H, D, —CH3, or —CF3.

### Claim 8 (depends on 3)

The compound of claim 3, wherein,
when X is C,
R1 and R2 are H, and R3 is H, D, or —CF3.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is selected from compounds of the following structures:

### Claim 10 (depends on 1)

A drug or a formulation containing the compound, or the pharmaceutically acceptable salt, the solvate, the isotope variant, or the isomer thereof claim 1.

### Claim 11 (depends on 10)

A method of treating a subject to a tumor, a cancer, or a cell proliferative disease, the method comprising:
administering to the subject the drug or the formulation of claim 10.

### Claim 12

(canceled)

### Claim 13 (depends on 11)

The method of the claim 11, wherein the tumor, the cancer comprises:
lung cancer, non-small cell lung cancer, liver cancer, pancreatic cancer, stomach cancer, bone cancer, esophagus cancer, breast cancer, prostate cancer, testicular cancer, colon cancer, ovarian cancer, bladder cancer, cervical cancer, melanoma, squamous-cell cancer, basal cell carcinoma, adenocarcinoma, squamous-cell carcinoma, sebaceous carcinoma, papillary carcinoma, papillary adenocarcinoma, cystadenocarcinoma, cystic carcinoma, medullary carcinoma, bronchial carcinoma, bone cell carcinoma, epithelial carcinoma, cholangiocarcinoma, choriocarcinoma, embryonic carcinoma, seminoma, Wilms' carcinoma, glioblastoma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, pineal tumor, hemoblastoma, neurogenic tumor of the larynx, meningiomas, neuroblastoma of optic nerve, neuroblastomas, retinoblastomas, neurofibromas, fibroma sarcomatosum, fibroblastomas, fibroma, fibroadenomas, fibrochondromas, fibrocystic tumors, fibrous myxoma, osterfibroma, myxofibrosarcoma, fibropapillary, myxofibrosarcoma, bursal tumor, myxonchondroma, myxonchondrosarcoma, myxonchondrosarcoma, myxedema, myxoblastoma, liposarcoma, lipoma, lipoadenoma, lipoblastoma, lipochondroma, lipofibroma, lipoangioma, myxolipoma, chondrosarcoma, chondroma, chondromyoma, chordoma, chorioadenoma, chorioepithelioma, chorioblastoma, osteosarcoma, osteoblastoma, osteochondrofibroma, osteochondrosarcoma, osteochondroma, osteocystoma, cementoma, osteofibroma, fibrosarcoma, angiosarcoma, hemangioma, angiolipoma, angiochondroma, hemangioblastoma, angiokeratoma, angioglioma, hemangioendothelioma, angiofibroma, angiomyoma, angiolipoma, angiolymphoma, angiolipiomyoma, angiomyolipomas, angiomyoneuroma, angiomyxoma, angioreticuloendothelioma, lymphangiosarcoma, lymphogranuloma, lymphangioma, lymphoma, lymphomyxoma, lymphosarcoma, lymphangial fibrom, lymphocytoma, lymphoepithelioma, lymphoblastoma, endothelioma, endothelioblastoma, synovialoma, synovial sarcoma, mesothelioma, desmoplastic tumor, Ewing's tumor, leiomyoma, leiomyosarcoma, leioblastoma, leiomyofibroma, rhabdomyoma, rhabdomyosarcoma, rhabdomyomatous myxoma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic disease cells, polycythemia, endometrial cancer, glioma, colorectal cancer, thyroid cancer, urothelial cancer, or multiple myeloma.

### Claim 14 (depends on 13)

The method of claim 13, wherein the tumor, or the cancer is selected from the non-small cell lung cancer, the pancreatic cancer, the breast cancer, or the prostate cancer.

### Claim 15 (depends on 13)

The method of claim 13, wherein the cancer, the tumor is a primary brain cancer, a brain tumor, or a metastatic cancer or a tumor which metastasize to a brain.

### Claim 16 (depends on 1)

A method of treating a patient with a damaged DNA repair, wherein the damaged DNA repair is a damaged homologous recombination DNA repair enzyme, or a damaged nucleotide excision repair enzyme, the method comprising:
preparing a drug with the compound, or the pharmaceutically acceptable salt, the solvate, the isotope variant, or the isomer thereof of claim 1 administering to the patient the drug.

### Claim 17 (depends on 1)

A compound drug, comprising the compound, or the pharmaceutically acceptable salt, the solvate, the isotope variant, or the isomer thereof in claim 1, and
a. a traditional chemotherapy drug;
b. an anti-angiogenic drug;
c. a cell checkpoint inhibitor; or
d. an immunosuppressant.

### Claim 18 (depends on 1)

A combination therapy for treating a cancer and a tumor, comprising:
administering to a patient a drug or a formulation containing the compound, or the pharmaceutically acceptable salt, the solvate, the isotope variant, or the isomer thereof claim 1; and
administering a traditional chemotherapy drug, an anti-angiogenic drug, a cell checkpoint inhibitor, or an immunosuppressant.

### Claim 19

(canceled)

### Claim 20

(canceled)

### Claim 21

(canceled)

### Claim 22 (depends on 3)

A method for preparing the compound of claim 3, wherein,
the method is carried out by adopting a first scheme, the method comprising the following steps:
providing the compound of formula (II) by undergoing a condensation reaction of a compound A to close a ring:
or
the method is carried out by adopting a second scheme, the method comprising the following steps:
providing the compound of formula (II) by reacting a compound B with R1H
wherein Y1 and Y2 are both leaving groups, and preferably, Y1 and Y2 are each respectively Cl, Br, I, —OTs, —ONO2, —OMs, —OTf, or —OSO2Cl.

### Claim 23 (depends on 22)

The method of claim 22, wherein in the first scheme, DIPEA or TEA is used as an anti-acid agent, and silver oxide or sliver nitrate is used as catalyst; or
in the second scheme, an alkali is added in a reaction process.

### Claim 24

A method of treating a subject to a primary brain cancer, a brain tumor, or a metastatic cancer or a tumor metastasizing to a brain, the method comprising:
preparing a drug with a compound of the following formula; and
administering to the patient the drug;

### Claim 25 (depends on 22)

The method of claim 22, wherein the Y1 is Br in the compound A, and Y2 is F in the compound B.
